Your point about the market wanting confirmation about the drugs working on the broader population is spot on.
Recce looks to have reached a point where it has established a lot of 'pre-trial' results that have laid the foundation for moving into various types of human trials, but increasingly the market wants to see all of this potential realised and proven through such trials.
The burns trial results, the sepsis trial results, and given the latest announcement, getting a sinusitis trial up and running plus results are the sorts of drivers that the market will value the most going forward.
Ann: Positive Sinusitis Patient Update - Special Access Scheme, page-91
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.010(3.33%) |
Mkt cap ! $89.39M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.0¢ | $25.76K | 82.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13550 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18938 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |